Taraxasterol
Based on 4 publication(s) in Google Scholar
Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.41%
- CAS No.: 1059-14-9
- 화학식: C30H50O
- 분자량:426.72
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Lipid Compound Library
HY-L043
-
Medicine Food Homology Compound Library
HY-L055
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Angiogenesis-Related Compound Library
HY-L088
-
Lipid Metabolism Compound Library
HY-L091
-
Food-Sourced Compound Library
HY-L094
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Nuclear Receptor Compound Library
HY-L126
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Taraxasterol
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
WB
-
Flow Cytometry
-
ELISA
Biological Activity
Taraxasterol (5-18 μg/ml, 1 h) inhibits vascular inflammation in human umbilical vein endothelial cells by activating LXRα [3]. Taraxasterol (2.5-10 μg/ml, 24 h) exhibits anti-inflammatory effects on human osteoarthritic chondrocytes [5]. Taraxasterol (114.68 μM, 24 h) has anti-metastatic effects on prostate cancer cells [6]. Taraxasterol (5-18 μg/ml, 1 h) shows no cytotoxicity to human umbilical vein endothelial cells at concentrations below 15 μg/ml [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cells (HUVECs)
-
Concentration:2.5, 5, 10 μg/ml
-
Incubation Time:24 h
-
Result:Dose-dependently inhibited IL-1β-induced NF-κB activation.
-
Cell Line:Human osteoarthritic chondrocytes
-
Concentration:5-18 μg/ml
-
Incubation Time:1 h
-
Result:Did not have cytotoxic effects on HUVECs at the concentrations of 5, 10, and 15 μg/ml. Could decrease the viability of HUVECs at the concentration of 18 μg/ml.
-
Cell Line:Prostate cancer cell lines (PC3 cells)
-
Concentration:1, 2, 4, 8, 16, 32, 64, 128 μM
-
Incubation Time:24, 48, 72 h
-
Result:Reduced the survival rate of PC3 cells.
-
Cell Line:Prostate cancer cell lines (PC3 cells)
-
Concentration:114.68 μM
-
Incubation Time:24 h
-
Result:Decreased the potential for cell invasion by 54%.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lipopolysaccharide (HY-D1056)-induced acute lung injury mouse model
-
Dosage:2.5, 5, and 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), 8 h
-
Result:Inhibited the phosphorylation of IκB-α, p65 NF-κB, p46–p54 JNK, p42–p44 ERK, and p38 caused by Lipopolysaccharide (HY-D1056).
Chemical Information
-
CAS No. 1059-14-9
-
Appearance Solid
-
분자량 426.72
-
화학식 C30H50O
-
Color White to off-white
-
SMILES
CC(C)([C@]1([H])CC[C@@]([C@](CC[C@@](CC2)3C)4C)5C)[C@@H](O)CC[C@]1(C)[C@@]5([H])CC[C@]4([H])[C@@]3([H])[C@H](C)C2=C
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Am J Cancer Res
Taraxasterol exhibits dual biological effects on anti-aging and anti-cancer in lung cells. [Abstract]2024 Jun 15;14(6):2755-2769. PMID: 39005687
Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769. [Abstract]
Dose response curve of Taraxasterol (5, 10, 30, 50, 70, 90, 100 μM) treatment in TC-1 and MLE-12 cells.
Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769. [Abstract]
Effect of Taraxasterol (10, 30, 50 μM) on cellular senescence determined by SpiDER-β-Gal staining.
Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769. [Abstract]
Effect of Taraxasterol (10, 30, 50 μM) on the expression of p16 and p21 determined by WB.
Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769. [Abstract]
Effect of Taraxasterol (10, 30, 50 μM) on cell cycle progression determined by Flow Cytometry.
Taraxasterol purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2024 Jun 15;14(6):2755-2769. [Abstract]
Taraxasterol (10, 30, 50 μM) decreased the secretion of IL-6/IL-1β as determined by ELISA analysis.
-
Cytotechnology
Taraxasterol mediated autophagy inhibition in pancreatic encephalopathy involves its regulation on L1 cell adhesion molecule. [Abstract]2025 Apr;77(2):72. PMID: 40051886 -
-
용액&용해도
Ethanol : 4 mg/mL (9.37 mM; Need ultrasonic)
DMSO : 1 mg/mL (2.34 mM; ultrasonic and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.55 mg/mL (1.29 mM); Clear solution
This protocol yields a clear solution of ≥ 0.55 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (5.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 0.55 mg/mL (1.29 mM); Clear solution
This protocol yields a clear solution of ≥ 0.55 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (5.5 mg/mL) to 900 μL Corn oil, and mix evenly.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2.5 mg/mL (5.86 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang X, et al. Effects of taraxasterol on inflammatory responses in lipopolysaccharide-induced RAW 264.7 macrophages. J Ethnopharmacol. 2012 May 7;141(1):206-11. [Content Brief]
[2]. Sang R, Yu Y, Ge B, Xu L, Wang Z, Zhang X. Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-κB and Bax/Bc1-2 signalling pathways. Artif Cells Nanomed Biotechnol. 2019;47(1):3929-3937. [Content Brief]
[3]. Zheng F, et al. Anti-inflammatory effects of taraxasterol on LPS-stimulated human umbilical vein endothelial cells[J]. Inflammation, 2018, 41: 1755-1761. [Content Brief]
[4]. San Z, et al. Protective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in mice[J]. International Immunopharmacology, 2014, 19(2): 342-350. [Content Brief]
[5]. Piao T, et al.Taraxasterol inhibits IL-1β-induced inflammatory response in human osteoarthritic chondrocytes. Eur J Pharmacol. 2015 Jun 5;756:38-42. [Content Brief]
[6]. Movahhed M, et al. Anti-metastatic effect of taraxasterol on prostate cancer cell lines. Res Pharm Sci. 2023 Jun 1;18(4):439-448. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 2.3435 mL | 11.7173 mL | 23.4346 mL | 58.5864 mL |
| Ethanol | 5 mM | 0.4687 mL | 2.3435 mL | 4.6869 mL | 11.7173 mL |
Taraxasterol Related Classifications
HY-N1178 Related Classifications
Powered by Bioz